File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: The use of estrogen in the treatment of Parkinson's disease

TitleThe use of estrogen in the treatment of Parkinson's disease
Authors
KeywordsCatechol-O-methyltransferase (COMT)
Estrogen
Parkinson's disease
Selective estrogen receptor modulators (SERM)
Issue Date2001
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/parkreldis
Citation
The 5th International Symposium on the Treatment of Parkinson's Disease, Kobe, Japan, 30 September-1 October in 2000. In Parkinsonism & Related Disorders, 2001, v. 8 n. 2, p. 133-137 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/163552
ISSN
2023 Impact Factor: 3.1
2023 SCImago Journal Rankings: 1.015
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTsang, KLen_US
dc.contributor.authorJiang, Hen_US
dc.contributor.authorRamsden, DBen_US
dc.contributor.authorHo, SLen_US
dc.date.accessioned2012-09-05T05:37:22Z-
dc.date.available2012-09-05T05:37:22Z-
dc.date.issued2001en_US
dc.identifier.citationThe 5th International Symposium on the Treatment of Parkinson's Disease, Kobe, Japan, 30 September-1 October in 2000. In Parkinsonism & Related Disorders, 2001, v. 8 n. 2, p. 133-137en_US
dc.identifier.issn1353-8020en_US
dc.identifier.urihttp://hdl.handle.net/10722/163552-
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/parkreldisen_US
dc.relation.ispartofParkinsonism & Related Disordersen_US
dc.subjectCatechol-O-methyltransferase (COMT)-
dc.subjectEstrogen-
dc.subjectParkinson's disease-
dc.subjectSelective estrogen receptor modulators (SERM)-
dc.subject.meshAntiparkinson Agents - Therapeutic Useen_US
dc.subject.meshCorpus Striatum - Drug Effectsen_US
dc.subject.meshDopamine - Metabolismen_US
dc.subject.meshEstrogens - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHormone Replacement Therapyen_US
dc.subject.meshHumansen_US
dc.subject.meshMenstrual Cycleen_US
dc.subject.meshMethyltransferases - Metabolismen_US
dc.subject.meshNeuroprotective Agents - Therapeutic Useen_US
dc.subject.meshParkinson Disease - Drug Therapy - Physiopathologyen_US
dc.subject.meshSex Characteristicsen_US
dc.subject.meshSubstantia Nigra - Drug Effectsen_US
dc.titleThe use of estrogen in the treatment of Parkinson's diseaseen_US
dc.typeConference_Paperen_US
dc.identifier.emailHo, SL:slho@hku.hken_US
dc.identifier.authorityHo, SL=rp00240en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S1353-8020(01)00027-Xen_US
dc.identifier.pmid11489678-
dc.identifier.scopuseid_2-s2.0-0034899543en_US
dc.identifier.hkuros82353-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0034899543&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume8en_US
dc.identifier.issue2en_US
dc.identifier.spage133en_US
dc.identifier.epage137en_US
dc.identifier.isiWOS:000171220400009-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridTsang, KL=7201554745en_US
dc.identifier.scopusauthoridJiang, H=36077295400en_US
dc.identifier.scopusauthoridRamsden, DB=7102612805en_US
dc.identifier.scopusauthoridHo, SL=25959633500en_US
dc.customcontrol.immutablesml 160303 - amend-
dc.identifier.issnl1353-8020-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats